Vardenafil dosing

Sildenafil doses should be decreased when any potent cytochrome P450 3A4 inhibitor is used (e g., cimetidine, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, and saquinavir). Vardenafil doses vary accordingto which agent is used (2.5 mg q 72 h for ritonavir, 2.5 mg q 24 h for indinavir, ketoconazole 400 mg daily, and itraconazole 400 mg daily and 5 mg q 24 h for ketoconazole 200 mg daily, itraconazole200 mg daily, and erythromycin). Tadalafil doses are reduced only when it is used with the most potent cytochrome P450 3A4 inhibitors (e g., ketoconazole or ritonavir). 

For maximal absorption, patients should avoid taking sildenafil or vardenafil with a fatty meal. A fatty meal does not affect absorption of tadalafil. / If the first dose is not effective, patients should continue trying for five to eight doses. Some patients benefit from titration up to 100 mg of sildenafil, 20 mg of vardenafil, or 20 mg of tadalafil. 

Sildenafil and vardenafil decrease systolic/diastolic blood pressure by 8 to 10/5 to 6 mm Hg for 1 to 4 hours after a dose. Although most patients are asymptomatic, multiple antihypertensives, nitrates, and baseline hypotension increase the risk of developing adverse effects. Although tadalafil does not decrease blood pressure, it should be used with caution in patients with cardiovascular disease because of the inherent risk associated with sexual activity. 

VARDENAFIL HYDROCHLORIDE 10 mg taken orally approximately 60 minutes before sexual activity. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects. The maximum recommended dosing frequency is once daily. Vardenafil can be taken with or without food. 

Hepatic function impairment- A starting dose of 5 mg is recommended in patients with moderate hepatic impairment (Child-Pugh B). The maximum dose should not exceed 10 mg. Vardenafil has not been evaluated in patients with severe hepatic impairment (Child-Pugh C). 

Concomitant mecf/caf/ons - The dosage of vardenafil may require adjustment in patients receiving certain CYP3A4 inhibitors. For ritonavir, do not exceed a single dose of 2.5 mg vardenafil in a 72-hour period. For indinavir, ketoconazole 400 mg/day, and itraconazole 400 mg/day, do not exceed a single dose of 2.5 mg vardenafil in a 24-hour period. For ketoconazole 200 mg/day, itraconazole 200 mg/day, and erythromycin, do not exceed a single dose of 5 mg vardenafil in a 24-hour period. 

Renal function impairment In volunteers with severe renal impairment (Ccr 30 mL/min or less), sildenafil clearance was reduced. Consider an initial sildenafil dose of 25 mg in these patients. There is no clinical data on the safety or efficacy of vardenafil in patients with end-stage renal disease requiring dialysis. 

Isosorbide Dinitrate Hydralazine (BiDil) [Antianginal, Antihypertensive/Vasodilator, Nitrate] Uses HF in African Amer-icans improve survival functional status, prolong time between hospitalizations Action Relaxes vascular smooth muscle peripheral vasodilator Dose Initially 1 tab tid PO (if not tol ated reduce to 1/2 tab tid), titrate >3-5 d as tolerated Max 2 tabs tid Caution [C, /-] recent MI, syncope, hypovolemia, hypotension, hep impair Contra For children, concomitant use w/ PDE5 inhibitors (sildenafil) Disp Tabs SE HA, dizziness, orthostatic hypotension, sinusitis, GI distress, tach, paresthesia, amblyopia Interactions t Risk of severe hypotension W/ antihypertensives, ASA, CCBs, MAOIs, phenothiazides, sildenafil, tadalafil, vardenafil, EtOH X pressor response Wf i -1- effects W7 NSAIDs EMS Use ASA, antihypertensives and CCBs w/ caution, may t hypotension concurrent Viagra-type drug use can lead to profound hypotension concurrent EtOH use can t effects OD May cause N/V, profound hypotension, skin flushing, HA from ICP, bradycardia, confusion, and circulatory collapse activated charcoal may be effective, epi use is contraindicated... 

MACROUDES PHOSPHODIESTERASE TYPE 5 INHIBITORS t phosphodiesterase type 5 inhibitor levels with erythromycin, and possibly clarithromycin and telithromycin Inhibition of metabolism 1 dose of these phosphodiesterase inhibitors (e.g. start vardenafil at 5 mg)... 

PROTEASE INHIBITORS PHOSPHODIESTERASE TYPE 5 INHIBITORS-SILDENAFIL, TADALAFIL, VARDENAFIL t sildenafil, tadalafil and vardenafil levels Inhibition of CYP3A4- and possibly CYP2C9-mediated metabolism of sildenafil Use with caution monitor BP closely. UK manufacturers recommend avoiding co-administration of vardenafil with protease inhibitors in patients >75 years. US manufacturers recommend using with caution, starting with a daily dose of 2.5 mg... 

PHOSPHODIESTERASE TYPE 5 INHIBITORS ANTIFUNGALS-AZOLES T sildenafil, tadalafil and vardenafil levels Inhibition of metabolism l dose of these phosphodiesterase type 5 inhibitors... 

PHOSPHODIESTERASE TYPE 5 INHIBITORS (e.g. sildenafil, tadalafil, vardenafil) GRAPEFRUIT JUICE Possibly t efficacy and t adverse effects, e.g. hypotension Small t in bioavailability, t variability in pharmacokinetics, i.e. interindividual variations in metabolism Safest to advise against intake of grapefruit juice for at least 48 hours prior to intending to take any of these preparations. When necessaiy, the starting dose of sildenafil should not exceed 25-50 mg and that of tadalafil 10 mg. Avoid co-administration with vardenafil... 

---